原料药 API
具备 GMP / DMF 注册就绪度的原料药（API）与候选药物 · 每条标明用途、适应症与为何值得上线
Listing Logic · Why These Products
This category is not a mere directory listing—each product is selected against the four criteria below and comes with both its 'use' and 'why it is listed' so buyers can quickly assess fit. Products are drawn from Unibest's API & Candidates supply catalog and posted after dual qualification and demand screening.
We prioritize APIs already GMP/DMF-ready that can directly support regulatory filing, avoiding the compliance cost of building from scratch.
We target chronic long-term therapies, (WHO) public-health procurement and specialty must-have scenarios with low, predictable demand volatility.
We include first-in-class mechanisms, first approvals or molecules addressing resistance/unmet need, offering differentiated pricing power.
We also tag the number of linked intermediates—deeper in-house intermediate coverage means higher feasibility for scale-up and cost reduction.
Browse by Indication
Pick a class to see only APIs for that disease areaDiabetes, obesity, dyslipidemia, NASH and other metabolic diseases
Hypertension, heart failure, anticoagulation, chronic kidney disease
Solid tumours, haematologic malignancies, myeloproliferative diseases
Antiviral, antibacterial, antifungal, HIV / hepatitis
RA, psoriasis, atopic dermatitis, IBD
Epilepsy, pain, depression & anxiety, neurodegeneration
Acid-related, GI motility, diarrhoea, liver disease
COPD, asthma and other airway diseases
Menopausal symptoms, urological conditions
Glaucoma, ocular surface disease
Skin infection, dermatologic inflammation
Local anaesthesia, postoperative analgesia
Allergic rhinitis, urticaria
Companion-animal ectoparasiticides
Browse by Patent Expiry
The cliff decides when to act — filter by window firstCompound patent expired — generic sourcing and registration feasible
Cliff approaching — lock in API supply and filing schedule early
Mid-term opportunity — start process development and DMF work
Still on-patent — typically licensing or clinical supply
No expiry on file — request a patent assessment for this molecule
Expiry years are compiled from public sources and estimated on compound patents in major markets (US / EU). They exclude polymorph, process and formulation patents, term extensions and paediatric exclusivity. Values marked indicative are directional; values marked to-verify are inferred from filing era. Actual generic entry timing depends on national patent offices and the Orange Book.
Fluralaner
Long-acting eradication of fleas and ticks in dogs and cats
A mainstream pet parasiticide with single-dose long protection; rising global pet-care spending sustains growing animal-health API demand.
- CAS
- 864731-61-3
- Therapeutic Area
- Animal Health
- Labeled Purity
- 99%+
Afoxolaner
Prevention and treatment of flea, tick and certain mite infestations in dogs and cats
A core oral pet parasiticide with good palatability and monthly dosing, often combined with milbemycin oxime, enabling fixed-combination product lines.
- CAS
- 1093861-60-9
- Therapeutic Area
- Animal Health
- Labeled Purity
- 98%+
Lotilaner
Ectoparasite control in dogs and cats; ophthalmic use for demodex blepharitis
The only isoxazoline expanded into human ophthalmology (demodex blepharitis), combining a steady animal-health base with a human-use upside option.
- CAS
- 1369852-71-0
- Therapeutic Area
- Animal Health / Ophthalmology
- Labeled Purity
- 98%+
Sarolaner
Prevention and treatment of flea, tick and other ectoparasite infestations in dogs and cats
One of several same-class agents, suitable as a combination supply within an animal-health portfolio to meet customers' generic and differentiated sourcing needs.
- CAS
- 1398609-39-6
- Therapeutic Area
- Animal Health
- Labeled Purity
- 98%+
Supply source: Unibest API & Candidates supply catalog, sourced and delivered by Unibest. Therapeutic area, indication and selection rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability is subject to DMF/GMP documentation and the technical agreement confirmed at order.